Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
506 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA, Kiladjian JJ, Catalano JV, et al. · J Clin Oncol · 2017Clinical Trial, Phase III, Comparative Study
- Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.
Appeldoorn TYJ, Munnink THO, Morsink LM, et al. · Clin Pharmacokinet · 2023Systematic Review
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S, Mesa RA, Gotlib J, et al. · N Engl J Med · 2012Clinical Trial, Phase III, Comparative Study
- Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, et al. · Lancet · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Extramedullary hemopoiesis.
Orphanidou-Vlachou E, Tziakouri-Shiakalli C, Georgiades CS · Semin Ultrasound CT MR · 2014Systematic Review
- Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
Rampal RK, Grosicki S, Chraniuk D, et al. · Nat Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A, Harrison C, Cortes JE, et al. · JAMA Oncol · 2015Clinical Trial, Phase III, Multicenter Study
- Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R, Finazzi G, Specchia G, et al. · N Engl J Med · 2013Comparative Study, Multicenter Study
- Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.
Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al. · Blood · 2015Clinical Trial, Multicenter Study
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN, Vannucchi AM, Platzbecker U, et al. · Lancet Haematol · 2018Clinical Trial, Phase III, Randomized Controlled Trial
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C, Kiladjian JJ, Al-Ali HK, et al. · N Engl J Med · 2012Clinical Trial, Phase III, Comparative Study
- Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
Gupta V, Oh S, Devos T, et al. · Leuk Lymphoma · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J, Hoffman R, Talpaz M, et al. · JAMA Oncol · 2018Randomized Controlled Trial
- Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.
Bruedigam C, Porter AH, Song A, et al. · Nat Cancer · 2024Clinical Trial, Phase II, Randomized Controlled Trial
- Management of Myeloproliferative Neoplasms (MPNs).
Nurgat Z, Lawrence M · J Oncol Pharm Pract · 2022Systematic Review
- MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
Mascarenhas J, Kremyanskaya M, Patriarca A, et al. · J Clin Oncol · 2023Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
Harrison CN, Vannucchi AM, Kiladjian JJ, et al. · Leukemia · 2016Clinical Trial, Phase III, Randomized Controlled Trial
- Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
Harrison CN, Vannucchi AM, Recher C, et al. · Adv Ther · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek S, Mesa RA, Gotlib J, et al. · J Hematol Oncol · 2017Clinical Trial, Phase III, Multicenter Study
- Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
Pardanani A, Tefferi A, Masszi T, et al. · Br J Haematol · 2021Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.
Harrison CN, Mesa R, Talpaz M, et al. · Lancet Haematol · 2024Multicenter Study, Clinical Trial, Phase III
- Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis.
Bewersdorf JP, Giri S, Wang R, et al. · Clin Lymphoma Myeloma Leuk · 2020Meta-Analysis, Research Support, N.I.H., Extramural
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Verstovsek S, Gotlib J, Mesa RA, et al. · J Hematol Oncol · 2017Randomized Controlled Trial
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA, Vannucchi AM, Mead A, et al. · Lancet Haematol · 2017Clinical Trial, Phase III, Comparative Study
- Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.
Sørensen AL, Skov V, Kjær L, et al. · Blood Adv · 2024Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.